| A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) (NCT07654374) | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2026-07-17 |
| Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1) (NCT07654361) | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2026-07-13 |
| Aleniglipron Phase 2 in Type 2 Diabetes Mellitus (NCT07400588) | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2025-12-01 |
| Aleniglipron Phase 2 Body Composition Study (NCT07169942) | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2025-08-15 |
| A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity (NCT06703021) | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2024-12-20 |
| A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity (NCT06693843) | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2024-10-28 |
| A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants (NCT06139055) | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2023-10-02 |
| A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants (NCT05893043) | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2023-04-24 |
| Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (NCT05762471) | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2023-01-09 |